FY2025 EPS Estimates for Rezolute Boosted by HC Wainwright

Rezolute, Inc. (NASDAQ:RZLT) – Equities researchers at HC Wainwright lifted their FY2025 EPS estimates for Rezolute in a note issued to investors on Thursday, May 15th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($0.91) for the year, up from their previous estimate of ($0.96). HC Wainwright has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for Rezolute’s current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Rezolute’s Q4 2025 earnings at ($0.20) EPS, Q1 2026 earnings at ($0.23) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.27) EPS, Q4 2026 earnings at ($0.30) EPS, FY2026 earnings at ($1.04) EPS, FY2027 earnings at ($1.14) EPS, FY2028 earnings at ($0.59) EPS and FY2029 earnings at ($0.40) EPS.

A number of other equities research analysts also recently weighed in on the stock. Craig Hallum upgraded shares of Rezolute to a “strong-buy” rating in a research note on Tuesday, February 4th. Guggenheim reiterated a “buy” rating on shares of Rezolute in a research note on Monday, February 10th. Wedbush restated an “outperform” rating and issued a $12.00 target price on shares of Rezolute in a research note on Wednesday, May 14th. Finally, JMP Securities boosted their target price on shares of Rezolute from $8.00 to $9.00 and gave the company a “market outperform” rating in a research note on Thursday, February 13th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Rezolute currently has an average rating of “Buy” and a consensus target price of $12.14.

Rezolute Trading Up 3.9%

Shares of Rezolute stock opened at $3.95 on Monday. The company’s fifty day simple moving average is $3.24 and its 200-day simple moving average is $4.28. The company has a market cap of $239.11 million, a price-to-earnings ratio of -3.24 and a beta of 1.01. Rezolute has a 1 year low of $2.22 and a 1 year high of $6.19.

Rezolute (NASDAQ:RZLT) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.05).

Institutional Investors Weigh In On Rezolute

A number of large investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. acquired a new stake in shares of Rezolute in the 1st quarter valued at approximately $685,000. Paloma Partners Management Co acquired a new stake in shares of Rezolute in the 1st quarter valued at approximately $48,000. Cubist Systematic Strategies LLC boosted its stake in shares of Rezolute by 335.4% in the 1st quarter. Cubist Systematic Strategies LLC now owns 210,581 shares of the company’s stock valued at $611,000 after purchasing an additional 162,216 shares in the last quarter. OMERS ADMINISTRATION Corp boosted its stake in shares of Rezolute by 56.4% in the 1st quarter. OMERS ADMINISTRATION Corp now owns 118,900 shares of the company’s stock valued at $345,000 after purchasing an additional 42,900 shares in the last quarter. Finally, Affinity Asset Advisors LLC boosted its stake in shares of Rezolute by 7.9% in the 1st quarter. Affinity Asset Advisors LLC now owns 1,700,000 shares of the company’s stock valued at $4,930,000 after purchasing an additional 125,000 shares in the last quarter. 82.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Nevan C. Elam acquired 12,302 shares of the stock in a transaction on Thursday, March 27th. The shares were purchased at an average price of $2.85 per share, for a total transaction of $35,060.70. Following the transaction, the chief executive officer now directly owns 224,119 shares of the company’s stock, valued at approximately $638,739.15. This represents a 5.81% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Daron Evans acquired 10,000 shares of the stock in a transaction on Wednesday, March 26th. The shares were purchased at an average price of $2.89 per share, for a total transaction of $28,900.00. Following the transaction, the chief financial officer now directly owns 237,900 shares in the company, valued at approximately $687,531. This trade represents a 4.39% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 29,060 shares of company stock valued at $83,694. 18.39% of the stock is owned by insiders.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.